Specialist insurer Beazley has appointed Prashansa Daga as Miscellaneous Medical & Life Sciences underwriter to support the expansion of its Healthcare offering in Asia Pacific.

Prashansa brings more than 15 years of insurance industry experience across both underwriting and broking. Her most recent role was at Marsh Singapore where she led the Asia Life Sciences team managing major accounts and focusing on Complex Casualty, Directors & Officers and Cyber risks.

Before joining Marsh Singapore in 2017, Prashansa spent eight years at Marsh India based in Mumbai as Casualty & Crisis Practice Leader. She began her insurance career as a Casualty & Financial Lines underwriter with Tata AIG within the Mumbai & Bangalore branch.

Beazley has been extending its Miscellaneous Medical & Life Sciences offering internationally in recent years having become an established market in North America for more than two decades. In Asia, this has included the launch in 2020 of Beazley’s pioneering Virtual Care product, which provides cover for health and technology-related risks facing digital health and wellness professionals. Beazley intends to introduce a tailored professional liability offering for the life sciences sector in Asia in 2021.

Evan Smith, global head of Miscellaneous Medical & Life Sciences at Beazley, said: “We’re expanding our offering globally as demand grows for specialist insurance to help manage the evolving risks driven by digital transformation within healthcare and increased investment and innovation in life sciences. Prashansa’s deep market knowledge and experience will help us to build compelling offerings that provide protection and support growth as the healthcare and life sciences markets in Asia develop.”

Lucien Mounier, Beazley’s Head of Asia Pacific, said: “As we introduce more specialist products to Asia, we are building a great team of underwriters who know this market well and have strong relationships with brokers and clients. Prashansa brings demonstrable leadership and experience and will be instrumental as we build our healthcare and life sciences footprint.”